LSD’s Depression Win; Summer Heat and Suicide; Antipsychotic Nonresponse Predictors

Topline data showed that a single dose of an investigational LSD-based pill (DT120) met primary and key secondary endpoints in a phase III trial of adults with major depressive disorder, developer Definium Therapeutics said.

Despite a recent executive order fast-tracking psychedelic drug research, drugmakers don’t expect third-party manufacturers to boost their psychedelic services right now. (Endpoints News)

Summer heat was linked with higher suicide rates among late adolescents and young adults, CDC and census data showed. (American Journal of Psychiatry)

In a randomized trial of adults with treatment-resistant depression, connectivity-based targeting of accelerated transcranial magnetic stimulation was superior to scalp-based targeting. (JAMA Psychiatry)

Health Secretary Robert F. Kennedy Jr. announced over $700 million in new funding to address mental illness, addiction, and homelessness.

The Washington Post looked at recent research about cannabis and its effects on the brain.

Luigi Mangione’s lawyers told a judge that he will no longer be asserting a psychiatric defense at his state murder trial over the killing of UnitedHealthcare CEO Brian Thompson. (AP)

Antipsychotic nonresponse in psychosis was tied to elevations in markers of glutamatergic and neuroinflammatory pathways, a mega-analysis of individual-level data found. (JAMA Psychiatry)

The New York Times examined research suggesting that anti-inflammatory drugs may have a role in treating some people with depression and looked at how chronic mental illness may shape people’s decisions about parenthood.

One in eight adults age 25 and under reported suicidal thoughts and behaviors but fewer than half received any mental health care, data from the National Survey on Drug Use and Health showed. (JAMA Pediatrics)

The FDA rejected cytisinicline to treat nicotine dependence, citing labeling and third-party manufacturing issues, Achieve Life Sciences said.

Investigational ML-004, an immediate and extended-release formulation of the migraine drug zolmitriptan, failed to improve social communication deficits in adolescents with autism spectrum disorder in a phase II trial, said MapLight Therapeutics.

Authors of a Lancet Psychiatry review delved into the rationale, strategies, and ethical considerations of harnessing placebo effects and mitigating nocebo effects in clinical practice.

A parliamentary committee in Canada recommended against expanding medical assistance in dying to include people whose sole underlying condition is a mental illness. (CBC)

Rapper Lil Nas X said he’s “doing much better” after receiving care for bipolar disorder at a mental health treatment facility. (ABC News)